4D Molecular Therapeutics, Inc.
FDMT
$14.34
-$0.30-2.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -179.18M | -160.90M | -140.11M | -209.18M | -196.14M |
| Total Depreciation and Amortization | 8.13M | 7.93M | 7.63M | 7.43M | 7.13M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.08M | 14.93M | 17.23M | 18.55M | 19.46M |
| Change in Net Operating Assets | -1.10M | 8.59M | 6.17M | -301.00K | 3.16M |
| Cash from Operations | -156.07M | -129.45M | -109.08M | -183.50M | -166.39M |
| Capital Expenditure | 106.00K | 95.00K | -536.00K | -1.56M | -3.42M |
| Sale of Property, Plant, and Equipment | 0.00 | 11.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16.74M | -56.14M | -92.44M | 44.49M | 55.88M |
| Cash from Investing | -16.64M | -56.03M | -92.97M | 42.93M | 52.46M |
| Total Debt Issued | 19.26M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 146.66M | 124.44M | 112.96M | 1.58M | 2.03M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 165.92M | 124.44M | 112.96M | 1.58M | 2.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.79M | -61.04M | -89.10M | -138.98M | -111.90M |